Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study

Abstract

Introduction: While coformulated ledipasvir (90 mg)/sofosbuvir (400 mg) (LDV/SOF) is approved for the treatment of hepatitis C virus (HCV) genotype 2 (GT2) infection in Taiwan, Japan, and New Zealand, data regarding its use for HIV (Human Immunodeficiency Virus)positive patients infected with HCV GT2 are sparse. We aimed to assess the effectiveness and tolerability of LDV/SOF for HIV-positive patients with HCV GT2 coinfection. Methods: From January 2019 to July 2020, consecutive HIV-positive Taiwanese patients infected with HCV GT2 who received LDV/SOF were retrospectively included for analysis. The effectiveness was determined by sustained virologic response 12 weeks off-therapy (SVR12).

Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations

“…The program had not reimbursed DAA retreatment for those who had ever received NHI-reimbursed DAAs until 2021, when a second course of DAAs could be reimbursed for those who had recurrent HCV infections due to relapse or reinfection. Enrollment in the HCV treatment program with achievement of SVR was high among PLWH ( 31 – 33 ).…”

Taiwan accelerates its efforts to eliminate hepatitis C

“…Also, we encourage the gastroenterologist to cooperate with nephrologist, psychiatrist and infectious disease physician to perform micro elimination in these high risk patients. The NHI agrees to expand prescription privilege to infectious disease physicians to treat dual HIV+HCV infected patients with DAA (25).…”